Autopsy report · NCT01615211

Randomized Study of Letrozole and Trilostane for Medical Abortion

“No access to study drug Trilostan. Company closed down”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 1 year 5 months before it stopped.
• 36 participants planned (an estimate, not an actual count).
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Kristina Gemzell Danielsson

Sponsor type

University, hospital or other

Conditions

Medical Abortion, Complete or Unspecified, Without Complication

Interventions

Letrozole; Trilostane

Participants

36 (planned, not actual)

Sites

1

Countries

Sweden

Trials that died the same way

• Exenatide For Reducing the Reinforcing Effects of Cocaine
  “The study was closed due to the inability to acquire the study drug.” (67% match in meaning)
• CMP-001 and INCAGN01949 for Patients With Stage IV Pancreatic Cancer and Other Cancers Except Melanoma
  “Study drug no longer available” (64% match in meaning)
• Phase II Study of Aldesleukin (IL-2) Following the Administration of Zanolimumab (Anti-CD4mAb) in Metastatic Melanoma and Metastatic Renal Cancer
  “The study was terminated because we were not able to obtain the study drug.” (62% match in meaning)
• Panobinostat/Velcade in Multiple Myeloma
  “This study was terminated because the drug company stopped making the study drug” (62% match in meaning)
• Letrozole and Celecoxib in Treating Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer
  “study drug unavailable” (60% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.